Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bioventus (BVS) EBT Margin (2020 - 2025)

Bioventus (BVS) has disclosed EBT Margin for 6 consecutive years, with 8.96% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT Margin rose 899.0% year-over-year to 8.96%, compared with a TTM value of 4.53% through Dec 2025, up 1366.0%, and an annual FY2025 reading of 4.53%, up 1366.0% over the prior year.
  • EBT Margin was 8.96% for Q4 2025 at Bioventus, up from 3.37% in the prior quarter.
  • Across five years, EBT Margin topped out at 29.9% in Q2 2021 and bottomed at 101.47% in Q4 2022.
  • Average EBT Margin over 5 years is 12.56%, with a median of 4.01% recorded in 2024.
  • The sharpest move saw EBT Margin plummeted -9858bps in 2022, then soared 9469bps in 2023.
  • Year by year, EBT Margin stood at 2.11% in 2021, then crashed by -1123bps to 25.78% in 2022, then soared by 76bps to 6.21% in 2023, then surged by 99bps to 0.03% in 2024, then surged by 26065bps to 8.96% in 2025.
  • Business Quant data shows EBT Margin for BVS at 8.96% in Q4 2025, 3.37% in Q3 2025, and 6.98% in Q2 2025.